About CoLucid Pharmaceuticals (NASDAQ:CLCD)
CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:CLCD
- CUSIP: N/A
- Web: www.colucid.com
Average Prices:- 50 Day Moving Avg: $44.95
- 200 Day Moving Avg: $33.88
- 52 Week Range: $5.26 - $46.65
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -25.85
- P/E Growth: 0.00
Profitability:- Return on Equity: -83.51%
- Return on Assets: -70.62%
Debt:- Current Ratio: 11.31%
- Quick Ratio: 11.30%
Misc:- Average Volume: 543,728 shs.
- Beta: 1.51
Frequently Asked Questions for CoLucid Pharmaceuticals (NASDAQ:CLCD)
What is CoLucid Pharmaceuticals' stock symbol?
CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."
How were CoLucid Pharmaceuticals' earnings last quarter?
CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) released its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.79) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.79). View CoLucid Pharmaceuticals' Earnings History.
Where is CoLucid Pharmaceuticals' stock going? Where will CoLucid Pharmaceuticals' stock price be in 2017?
5 brokerages have issued twelve-month target prices for CoLucid Pharmaceuticals' stock. Their predictions range from $40.00 to $52.00. On average, they anticipate CoLucid Pharmaceuticals' stock price to reach $45.88 in the next twelve months. View Analyst Ratings for CoLucid Pharmaceuticals.
Who are some of CoLucid Pharmaceuticals' key competitors?
Some companies that are related to CoLucid Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), Novo Nordisk A/S (NVO), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA) and Dr. Reddy's Laboratories Ltd (RDY).
When did CoLucid Pharmaceuticals IPO?
(CLCD) raised $55 million in an IPO on Wednesday, May 6th 2015. The company issued 5,500,000 shares at a price of $10.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and William Blair was co-manager.
How do I buy CoLucid Pharmaceuticals stock?
Shares of CoLucid Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CoLucid Pharmaceuticals' stock price today?
One share of CoLucid Pharmaceuticals stock can currently be purchased for approximately $46.53.
MarketBeat Community Rating for CoLucid Pharmaceuticals (NASDAQ CLCD)MarketBeat's community ratings are surveys of what our community members think about CoLucid Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for CoLucid Pharmaceuticals (NASDAQ:CLCD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.40) |
| Consensus Price Target: | $45.88 (1.41% downside) |
Consensus Price Target History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Analysts' Ratings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/23/2017 | Barclays PLC | Downgrade | Overweight -> Equal Weight | $45.00 | N/A |  |
| 1/18/2017 | BTIG Research | Set Price Target | Buy | $52.00 | N/A | |
| 1/18/2017 | William Blair | Downgrade | Outperform -> Market Perform | | N/A | |
| 1/18/2017 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | $49.00 -> $46.50 | N/A | |
| 10/24/2016 | Stifel Nicolaus | Boost Price Target | Buy | $30.00 -> $40.00 | N/A | |
| 9/19/2016 | Ladenburg Thalmann Financial Services | Set Price Target | Buy | $57.00 | N/A | |
(Data available from 10/17/2015 forward)
Earnings History for CoLucid Pharmaceuticals (NASDAQ:CLCD)Earnings History by Quarter for CoLucid Pharmaceuticals (NASDAQ CLCD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2016 | 9/30/2016 | ($0.79) | ($0.79) | | | View | N/A | |
| 8/10/2016 | Q2 | ($0.84) | ($1.06) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.73) | ($0.85) | | | View | N/A | |
| 3/2/2016 | Q4 2015 | ($0.64) | ($0.74) | | | View | N/A | |
| 11/10/2015 | Q3 | ($0.63) | ($0.59) | | | View | N/A | |
| 8/12/2015 | Q2 2015 | ($0.40) | ($1.17) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for CoLucid Pharmaceuticals (NASDAQ:CLCD)Current Year EPS Consensus Estimate: $-3.46 EPS
Next Year EPS Consensus Estimate: $-1.80 EPS
Dividend History for CoLucid Pharmaceuticals (NASDAQ:CLCD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for CoLucid Pharmaceuticals (NASDAQ:CLCD)Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 64.17%
Insider Trades by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/5/2017 | Linda C Hogan | Insider | Sell | 2,580 | $35.18 | $90,764.40 | |
| 1/5/2017 | Thomas P Mathers | CEO | Sell | 1,502 | $34.78 | $52,239.56 | |
| 1/3/2017 | Bernice Kuca | Insider | Sell | 772 | $36.25 | $27,985.00 | |
| 1/3/2017 | Matthew D Dallas | CFO | Sell | 1,473 | $36.25 | $53,396.25 | |
| 12/5/2016 | Linda C Hogan | Insider | Sell | 2,583 | $37.77 | $97,559.91 | |
| 12/5/2016 | Thomas P. Mathers | CEO | Sell | 1,502 | $38.75 | $58,202.50 | |
| 12/1/2016 | Bernice Kuca | Insider | Sell | 772 | $35.22 | $27,189.84 | |
| 12/1/2016 | Matthew D. Dallas | CFO | Sell | 1,473 | $35.17 | $51,805.41 | |
| 11/7/2016 | Linda C Hogan | Insider | Sell | 1,862 | $28.56 | $53,178.72 | |
| 11/7/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $28.57 | $42,912.14 | |
| 11/1/2016 | Linda C Hogan | Insider | Sell | 719 | $30.00 | $21,570.00 | |
| 10/5/2016 | Linda C Hogan | Insider | Sell | 2,581 | $37.22 | $96,064.82 | |
| 10/5/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $37.08 | $55,694.16 | |
| 9/14/2016 | Thomas P Mathers | CEO | Sell | 6,000 | $23.32 | $139,920.00 | |
| 9/9/2016 | A/S Novo | Major Shareholder | Buy | 100,000 | $20.00 | $2,000,000.00 | |
| 9/7/2016 | Thomas P Mathers | CEO | Sell | 6,502 | $21.72 | $141,223.44 | |
| 9/6/2016 | Linda C Hogan | Insider | Sell | 48,736 | $19.87 | $968,384.32 | |
| 8/31/2016 | Raymond Skwierczynski | Insider | Sell | 150 | $10.86 | $1,629.00 | |
| 8/19/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.41 | $4,272.28 | |
| 8/10/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.30 | $4,216.40 | |
| 8/5/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $8.31 | $12,481.62 | |
| 8/3/2016 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 153,028 | $8.45 | $1,293,086.60 | |
| 7/29/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $9.09 | $4,617.72 | |
| 7/20/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $8.97 | $4,556.76 | |
| 7/11/2016 | Raymond Skwierczynski | Insider | Sell | 508 | $9.10 | $4,622.80 | |
| 6/30/2016 | Raymond Skwierczynski | Insider | Sell | 516 | $7.01 | $3,617.16 | |
| 6/20/2016 | Raymond Skwierczynski | Insider | Sell | 1,008 | $6.80 | $6,854.40 | |
| 6/6/2016 | Thomas P Mathers | CEO | Sell | 1,502 | $7.25 | $10,889.50 | |
| 4/28/2016 | Vi Associates L.P. Dp | Major Shareholder | Sell | 235 | $6.96 | $1,635.60 | |
| 8/25/2015 | Thomas P Mathers | CEO | Buy | 7,500 | $7.10 | $53,250.00 | |
| 5/11/2015 | A/S Novo | Major Shareholder | Buy | 1,300,000 | $10.00 | $13,000,000.00 | |
| 5/11/2015 | Arthur M Pappas | Director | Buy | 300,000 | $10.00 | $3,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for CoLucid Pharmaceuticals (NASDAQ:CLCD)
Latest Headlines for CoLucid Pharmaceuticals (NASDAQ:CLCD)
| Source: |
|
| Date | Headline |
|---|
 | Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
finance.yahoo.com - October 5 at 11:22 AM |
| Eli Lilly and Company -- Moody's: Eli Lilly and Company's acquisition of pipeline-stage asset is credit negative
finance.yahoo.com - October 5 at 11:22 AM |
| Here’s What You Need To Know About The Eli Lilly And Co (LLY) And CoLucid Pharmaceuticals Inc (CLCD) Deal
finance.yahoo.com - October 5 at 11:22 AM |
| Here's Why CoLucid Pharmaceuticals Inc Popped Yesterday
finance.yahoo.com - October 5 at 11:22 AM |
| Robbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. (CLCD) by Eli Lilly and Company (LLY) May Not Be in Shareholders' Best Interests
finance.yahoo.com - October 5 at 11:22 AM |
| COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and Company
finance.yahoo.com - October 5 at 11:22 AM |
| SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid Pharmaceuticals, Inc. -CLCD
finance.yahoo.com - October 5 at 11:22 AM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 11:22 AM |
| Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset
finance.yahoo.com - October 5 at 11:22 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - October 5 at 11:22 AM |
| INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 11:22 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
finance.yahoo.com - October 5 at 11:22 AM |
| Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - October 5 at 11:22 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders
finance.yahoo.com - October 5 at 11:22 AM |
| Lilly Completes Acquisition of CoLucid Pharmaceuticals
finance.yahoo.com - October 5 at 11:22 AM |
 | CoLucid Pharmaceuticals (CLCD) & Its Competitors Critical Comparison
www.americanbankingnews.com - October 1 at 6:30 PM |
| Reviewing Dr. Reddy's Laboratories (RDY) and CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - August 31 at 4:26 AM |
 | An experimental treatment for migraines just passed a critical study
www.businessinsider.com - May 12 at 9:56 PM |
 | 5 Top Technology Investments To Make In 2017
www.nasdaq.com - May 11 at 4:57 PM |
 | Eli Lilly & Co. (LLY) Completes Takeover of CoLucid Pharmaceuticals (CLCD) - StreetInsider.com
www.streetinsider.com - March 1 at 9:24 PM |
| COLUCID PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delis
biz.yahoo.com - March 1 at 9:24 PM |
 | Bragar Eagel & Squire, P.C. Is Investigating the Board …
uk.finance.yahoo.com - January 31 at 9:47 PM |
 | INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional ...
www.businesswire.com - January 30 at 10:14 PM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional ...
www.businesswire.com - January 23 at 4:37 PM |
 | SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM |
| COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals ... - PR Newswire (press release)
www.prnewswire.com - January 21 at 9:26 PM |
| CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in ... - PR Newswire (press release)
www.prnewswire.com - January 19 at 10:35 PM |
| Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M - StreetInsider.com
www.streetinsider.com - January 19 at 10:34 PM |
 | CoLucid Pharmaceuticals Inc. (CLCD) Leaped To A New High On Merger News
www.rttnews.com - January 19 at 5:33 PM |
CoLucid Pharmaceuticals (CLCD) Chart for Tuesday, October, 17, 2017
